Leflunomide Induced Toxic Epidermolysis Necrosis in Patient with Rheumatoid Arthritis

Authors

DOI:

https://doi.org/10.3126/jmmihs.v10i1.77690

Keywords:

Leflunomide, Epidermolysis, Rheumatoid Arthritis

Abstract

Leflunomide is immunomodulating agent used in rheumatoid arthritis and other rheumatic diseases like psoriatic arthritis and systemic lupus erythematous. Minor side effects of leflunomide (<10%) are rash, purpura but only severe case can lead to Steven johnson syndrome( SJS) or toxic epidermolysis. Causative agent (leflunomide) was discontinued and TEN was treated with methylprednisolone, cholestyramine and immunoglobulin. The skin lesion eventually resolved within 2-3 weeks with some hyperpigmentation.

Leflunomide is a drug that was used to prevent transplant rejection, however it’s use has been diversified in treating in rheumatic diseases, psoriatic arthritis and SLE.  Rheumatic diseases is autoimmune diseases that affects joints, tendon, muscle, ligaments, bones and muscles. We present the case of patient with rheumatic arthritis, who had been receiving leflunomide, prescribed by rheumatologist. The patient attends our hospital with picture of TEN after started using leflunomide

Downloads

Download data is not yet available.
Abstract
187
PDF
131
Cover JMMIHS

Downloads

Published

2025-04-28

How to Cite

Pyakurel, B., & Basnet, P. (2025). Leflunomide Induced Toxic Epidermolysis Necrosis in Patient with Rheumatoid Arthritis. Journal of Manmohan Memorial Institute of Health Sciences, 10(1), 12–14. https://doi.org/10.3126/jmmihs.v10i1.77690

Issue

Vol. 10 No. 1 (2025)

Section

Case Reports

License

Copyright on any research article in JMMIHS is retained by the author(s).
The authors grant JMMIHS a license to publish the article and identify itself as the original publisher.

The corresponding author is responsible for any conflict of interest between authors and others. The journal is not responsible for concepts, ideas, and views reflected in the articles published in the journal. The article will be retracted if any violation of an ethical issue is detected.

The articles in JMMIHS are licensed under a https://creativecommons.org/licenses/by/4.0/  (CC BY).
This license permits use, distribution, and reproduction in any medium, provided the original work is properly cited, and it is not used for commercial purposes.